{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:36:48Z","timestamp":1762522608814,"version":"3.40.4"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Multidrug-resistant Gram-negative bacteria remain a significant threat to patient and allograft survival. Management of these infections in solid organ transplant (SOT) recipients remains challenging due to a limited antimicrobial pipeline and reliance on novel agents, which have not been systematically evaluated in the transplant population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Novel antimicrobials, including the second-generation \u03b2-lactam\/\u03b2-lactamase inhibitors, cefiderocol, plazomicin and eravacycline, have been developed to combat infections due to multidrug-resistant Gram-negative infections, but each has microbiologic and therapeutic niches and warrant further study in SOT recipients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>This review summarizes therapeutic options for extended-spectrum \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales and <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic> with difficult-to-treat resistance in SOT recipients and emphasizes recently approved antimicrobial agents.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mot.0000000000000890","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T07:02:44Z","timestamp":1624258964000},"page":"424-431","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["New drugs for difficult bugs: management of multidrug-resistant gram-negative infections in solid organ transplant recipients"],"prefix":"10.1097","volume":"26","author":[{"given":"Stephanie M.","family":"Pouch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"R1-20250429","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s11908-013-0371-z","article-title":"Multidrug-resistant bacteria in organ transplantation: an emerging threat with limited therapeutic options","volume":"15","author":"Patel","year":"2013","journal-title":"Curr Infect Dis Rep"},{"key":"R2-20250429","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/tid.12356","article-title":"Nosocomial bloodstream infections in a nationwide study: comparison between solid organ transplant patients and the general population","volume":"17","author":"Camargo","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"R3-20250429","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/21505594.2016.1139279","article-title":"Bloodstream infections after solid-organ transplantation","volume":"7","author":"Kritikos","year":"2016","journal-title":"Virulence"},{"key":"R4-20250429","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/tri.12984","article-title":"Changing trends in the aetiology, treatment and outcomes of bloodstream infection occurring in the first year after solid organ transplantation: a single-centre prospective cohort study","volume":"30","author":"Oriol","year":"2017","journal-title":"Transpl Int"},{"issue":"(Suppl 7)","key":"R5-20250429","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/1469-0691.12687","article-title":"Multidrug-resistant bacteria in solid organ transplant recipients","volume":"20","author":"Cervera","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R6-20250429","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12879-017-2276-1","article-title":"Factors influencing mortality in abdominal solid organ transplant recipients with multidrug-resistant gram-negative bacteremia","volume":"17","author":"Qiao","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R7-20250429","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1111\/j.1600-6143.2007.01964.x","article-title":"Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain","volume":"7","author":"Moreno","year":"2007","journal-title":"Am J Transplant"},{"key":"R8-20250429","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/23744235.2015.1051106","article-title":"Predictors of shock and mortality in solid organ transplant recipients with bacteremia caused by nonlactose-fermenting gram-negative bacilli","volume":"48","author":"Wan","year":"2016","journal-title":"Infect Dis (Lond)"},{"key":"R9-20250429","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/ctr.12575","article-title":"Multidrug-resistant Acinetobacter baumannii infections in lung transplant patients in the cardiothoracic intensive care unit","volume":"29","author":"Biderman","year":"2015","journal-title":"Clin Transplant"},{"key":"R10-20250429","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/cid\/ciab295","article-title":"Infectious Diseases Society of America Guidance on the treatment of extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R11-20250429","doi-asserted-by":"crossref","first-page":"e13594","DOI":"10.1111\/ctr.13594","article-title":"Multidrug-resistant Gram-negative bacterial infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Pouch","year":"2019","journal-title":"Clin Transplant"},{"key":"R12-20250429","doi-asserted-by":"crossref","first-page":"e00749-17","DOI":"10.1128\/mBio.00749-17","article-title":"Widespread fosfomycin resistance in Gram-negative bacteria attributable to the chromosomal fosA gene","volume":"8","author":"Ito","year":"2017","journal-title":"mBio"},{"key":"R13-20250429","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1128\/AAC.00402-12","article-title":"Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms","volume":"56","author":"Neuner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20250429","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R15-20250429","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1128\/AAC.01477-15","article-title":"Cefepime therapy for monomicrobial Enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-20250429","doi-asserted-by":"crossref","first-page":"ofw132","DOI":"10.1093\/ofid\/ofw132","article-title":"Cefepime therapy for cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia","volume":"3","author":"Wang","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"R17-20250429","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli","volume":"56","author":"Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20250429","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"R19-20250429","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","author":"Henderson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R20-20250429","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation beta-lactam\/beta-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R21-20250429","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"R22-20250429","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/phar.2476","article-title":"Cefiderocol: a novel siderophore cephalosporin against multidrug-resistant Gram-negative pathogens","volume":"40","author":"Abdul-Mutakabbir","year":"2020","journal-title":"Pharmacotherapy"},{"key":"R23-20250429","doi-asserted-by":"crossref","first-page":"e01699-19","DOI":"10.1128\/AAC.01699-19","article-title":"In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-20250429","doi-asserted-by":"crossref","first-page":"e02068-18","DOI":"10.1128\/AAC.02068-18","article-title":"In vitro activity of plazomicin against Gram-negative and Gram-positive bacterial pathogens isolated from patients in Canadian hospitals from 2013 to 2017 as part of the CANWARD Surveillance Study","volume":"63","author":"Walkty","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20250429","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1128\/AAC.00548-15","article-title":"Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae","volume":"59","author":"Shields","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20250429","doi-asserted-by":"crossref","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-20250429","doi-asserted-by":"crossref","first-page":"e00642-17","DOI":"10.1128\/AAC.00642-17","article-title":"Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant enterobacteriaceae","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-20250429","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-20250429","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R30-20250429","doi-asserted-by":"crossref","first-page":"e00449-17","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"(Suppl 1)","key":"R31-20250429","article-title":"Application of \u2018precision medicine\u2019 through the molecular characterization of extensively drug resistant (XDR) Klebsiella pneumoniae in a multivisceral transplant candidate","volume":"3","author":"Rosa","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"R32-20250429","doi-asserted-by":"crossref","first-page":"e13510","DOI":"10.1111\/tid.13510","article-title":"Treatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime\/avibactam with aztreonam: a case series and literature review","volume":"23","author":"Cairns","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"R34-20250429","doi-asserted-by":"crossref","first-page":"S537","DOI":"10.1093\/ofid\/ofx163.1398","article-title":"Meropenem-vaborbactam vs. best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: outcomes in immunocompromised patients","volume":"4","author":"Paterson","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"R35-20250429","doi-asserted-by":"crossref","first-page":"e01551-18","DOI":"10.1128\/AAC.01551-18","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient","volume":"63","author":"Athans","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-20250429","doi-asserted-by":"crossref","first-page":"e02313-19","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R37-20250429","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/cid\/ciz1131","article-title":"Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"71","author":"Shields","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R38-20250429","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R39-20250429","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R40-20250429","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of Imipenem\/Cilastatin\/Relebactam versus Piperacillin\/Tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study)","author":"Titov","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R41-20250429","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R42-20250429","doi-asserted-by":"crossref","first-page":"e00948-19","DOI":"10.1128\/AAC.00948-19","article-title":"Coinfections of two strains of NDM-1- and OXA-232-coproducing Klebsiella pneumoniae in a kidney transplant patient","volume":"64","author":"Contreras","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R43-20250429","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"R44-20250429","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1128\/AAC.00556-09","article-title":"ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates","volume":"53","author":"Endimiani","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R45-20250429","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jac\/dkq408","article-title":"Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates","volume":"66","author":"Livermore","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R46-20250429","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/jac\/dkx261","article-title":"In vitro activity of plazomicin against beta-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE)","volume":"72","author":"Zhang","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R47-20250429","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"R48-20250429","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N Engl J Med"},{"key":"R49-20250429","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R52-20250429","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R53-20250429","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R54-20250429","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2014.04.004","article-title":"Ceftolozane\/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Infect"},{"key":"R55-20250429","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R56-20250429","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of Ceftolozane\/Tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R57-20250429","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R58-20250429","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1128\/AAC.03056-15","article-title":"In vitro activity of ceftazidime-avibactam against contemporary Pseudomonas aeruginosa isolates from U.S. Medical Centers by Census Region, 2014","volume":"60","author":"Huband","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R59-20250429","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1128\/AAC.02969-15","article-title":"Evaluation of the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against meropenem-resistant Pseudomonas aeruginosa isolates","volume":"60","author":"Buehrle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R60-20250429","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 noninferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R61-20250429","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/jac\/dky204","article-title":"Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam Phase III clinical trial programme","volume":"73","author":"Stone","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R62-20250429","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/jac\/dkz191","article-title":"Activity of imipenem\/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17","volume":"74","author":"Lob","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R63-20250429","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jac\/dkaa456","article-title":"Activity of imipenem\/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R64-20250429","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s15010-017-1086-0","article-title":"Ceftolozane\/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant","volume":"46","author":"Peghin","year":"2018","journal-title":"Infection"},{"key":"R65-20250429","first-page":"1402320","article-title":"Multidrug resistant Pseudomonas mycotic Pseudoaneurysm following cardiac transplant bridged by ventricular assistant device","volume":"2017","author":"Aye","year":"2017","journal-title":"Case Rep Infect Dis"},{"key":"R66-20250429","first-page":"8","article-title":"Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant Pseudomonas infection and renal insufficiency","volume":"23","author":"Stokem","year":"2018","journal-title":"Respir Med Case Rep"},{"key":"R67-20250429","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.transproceed.2020.02.051","article-title":"Use of ceftazidime-avibactam and ceftolozane-tazobactam after lung transplantation","volume":"52","author":"Amore","year":"2020","journal-title":"Transplant Proc"},{"key":"R68-20250429","first-page":"3346","article-title":"Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms","volume":"73","author":"Castanheira","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R69-20250429","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/jac\/dkq459","article-title":"Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City","volume":"66","author":"Landman","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R70-20250429","doi-asserted-by":"crossref","first-page":"e01968-17","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R71-20250429","doi-asserted-by":"crossref","first-page":"115012","DOI":"10.1016\/j.diagmicrobio.2020.115012","article-title":"In vitro activity of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacilli isolated from patients in Canadian intensive care units","volume":"97","author":"Golden","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R72-20250429","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1111\/ajt.15503","article-title":"Early clinical experience of bacteriophage therapy in 3 lung transplant recipients","volume":"19","author":"Aslam","year":"2019","journal-title":"Am J Transplant"},{"key":"R73-20250429","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"key":"R74-20250429","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/v13010060","article-title":"A case of phage therapy against Pandrug-resistant Achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient","volume":"13","author":"Lebeaux","year":"2021","journal-title":"Viruses"},{"key":"R75-20250429","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.healun.2019.01.001","article-title":"Novel bacteriophage therapy for treatment of left ventricular assist device infection","volume":"38","author":"Aslam","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"R76-20250429","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01281-19","article-title":"A Dutch case report of successful treatment of chronic relapsing urinary tract infection with bacteriophages in a renal transplant patient","volume":"64","author":"Kuipers","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R77-20250429","doi-asserted-by":"crossref","first-page":"e13391","DOI":"10.1111\/tid.13391","article-title":"Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy","volume":"23","author":"Rostkowska","year":"2021","journal-title":"Transpl Infect Dis"}],"container-title":["Current Opinion in Organ Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOT.0000000000000890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T21:10:38Z","timestamp":1745961038000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOT.0000000000000890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mot.0000000000000890","relation":{},"ISSN":["1087-2418","1531-7013"],"issn-type":[{"type":"print","value":"1087-2418"},{"type":"electronic","value":"1531-7013"}],"subject":[],"published":{"date-parts":[[2021,6,18]]}}}